August 27th, 2024 (Shanghai) — We are glad to announce that Kun-Po Li, the Director of Business Development of Immunwork, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the Western biopharma industry.
About Immunwork, Inc.
Immunwork, Inc. is a biotechnology company that specializes in developing innovative drugs using its proprietary “Multi-Arm Linker” platforms. The company’s platforms are designed to conjugate various drug moieties together and create new drugs, including antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and ultralong-acting peptides. These novel drugs address severe clinical conditions such as cancer, diabetes, obesity, and cardiovascular diseases, among others. The concept of “T-E pharmaceuticals,” which guides the company’s drug development efforts, involves creating drug molecules that contain both targeting (T) and effector (E) moieties. This approach ensures that the drugs are precisely delivered to specific tissues or cells, enhancing efficacy and minimizing toxicity.
Immunwork is committed to advancing its drug candidates into clinical applications to help patients in need. With the rise of personalized and precision medicine, Immunwork’s modular design feature, enabled by the T-E pharmaceuticals concept, is especially well-suited for developing a new generation of therapeutics. By leveraging its Multi-Arm Linker platform, Immunwork aims to create additional novel drug candidates that can address unmet medical needs in a variety of therapeutic areas.
About the speaker
Dr. Kun-Po Li, PhD, serves as the Director of Business Development at Immunwork and drives corporate strategy, fundraising, and oversees negotiations for licensing, term sheets, and contracts. His expertise extends to clinical development planning, translational research, and effective outsourcing management. Formerly at Sanofi as a Senior Scientist/Lab Supervisor, Dr. Li contributed to the evaluation of potentials of drug candidates, translational medicine studies, supporting immune-oncology, autoimmune, and rare disease pipelines. His comprehensive background also encompasses impactful roles at Compass Therapeutics, Inc., supporting innovative therapeutic antibody research.
Dr. Li received his PhD in Immunology from the University of Cincinnati and his MS and BS degrees from National Taiwan University.
About ACCESS CHINA Partnering Forum
ACCESS CHINA Partnering Forum – Autumn Virtual Showcase is scheduled to be held on September 24th to 25th, and 27th, 2024, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, audience can have access to innovative pharma and healthcare products from worldwide.
Conference Name: ACCESS CHINA Partnering Forum
Date & Time: Sep 24 – 25 (live), and 27 (VoD) 2024, China time
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 500+ participants Online; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs
View more information at https://biotochina.org/
REGISTER
To Register for ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 